Jade Biosciences (JBIO) Stock Price, News & Analysis

Company Overview

Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research and development efforts are directed toward antibody-based medicines designed to address significant unmet needs in immune-mediated conditions.

Jade’s pipeline includes investigational therapeutic programs intended to modulate biological pathways involved in inflammation and immune-system activity. As a development-stage company, its products remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or reach the commercial market.

The company is headquartered in the United States and is developing its portfolio for potential use in global markets. Publicly available information about Jade Biosciences’ commercial operations and marketed products remains limited because the company is focused primarily on advancing its clinical pipeline.

Key Stats

• Today's Range: $12.85 to $13.66
• 50-Day Range: $13.41 to $24.71
• 52-Week Range: $8.36 to $28.00
• Volume: 1.17 million shs
• Average Volume: 1.06 million shs
• Market Capitalization: $854.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.75
• Consensus Rating: Moderate Buy

Jade Biosciences Stock Analysis - MarketRank™

Jade Biosciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 645th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Jade Biosciences has a consensus price target of $51.75, representing about 285.0% upside from its current price of $13.44.

Amount of Analyst Coverage

Jade Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jade Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.11) per share.

Price to Book Value per Share Ratio

Jade Biosciences has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.77% of the float of Jade Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Jade Biosciences has a short interest ratio ("days to cover") of 11.33, which indicates bearish sentiment.

Change versus previous month

Short interest in Jade Biosciences has recently increased by 10.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jade Biosciences does not currently pay a dividend.

Dividend Growth

Jade Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Jade Biosciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Jade Biosciences this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for JBIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Jade Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:JBIO
• Previous Symbol: NASDAQ:JBIO
• CIK: 1798749
• Web: www.jadebiosciences.com
• Phone: (617) 443-2400
• Fax: N/A
• Employees: 55
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jade Biosciences: $51.75
• High Price Target: $77.00
• Low Price Target: $40.00
• Potential Upside/Downside: +285.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.11%
• Return on Assets: -45.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.93
• Quick Ratio: 14.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.74 per share
• Price / Book: 1.99

Miscellaneous

• Outstanding Shares: 63,600,000
• Free Float: 48,932,000
• Market Cap: $854.78 million
• Optionable: N/A
• Beta: 1.64